Grant: Proof of Principle Program - Phase I
University of British Columbia
$158,389.00
Novel compounds for treatment of pulmonary hypertension
EF 2012-13
Résumé
The objective of this project is to advance the development of the CAVOX lead compound, a novel short peptide that is a potential candidate for treatment of hypertension, especially pulmonary arterial hypertension. The proposal will specifically address whether the lead compound is a viable therapeutic for pulmonary hypertension and/or systemic hypertension, and includes lead optimization, efficacy, and pharmacokinetic studies.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
268545
Name
Bernatchez Pascal N
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Novel compounds for treatment of pulmonary hypertension
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$158,389
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cardiovascular Disease; Hypertension; Peptide; Pulmonary Areterial Hypertension; Respiratory Disease
Abstract
The objective of this project is to advance the development of the CAVOX lead compound, a novel short peptide that is a potential candidate for treatment of hypertension, especially pulmonary arterial hypertension. The proposal will specifically address whether the lead compound is a viable therapeutic for pulmonary hypertension and/or systemic hypertension, and includes lead optimization, efficacy, and pharmacokinetic studies.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bernatchez, Pascal N
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $158,389~ $0~
